NumFin

Adicet Bio, Inc.

Sümbol: ACET

NASDAQ

1.69

USD

Turuhind täna

  • -0.5143

    P/E suhe

  • 0.0002

    PEG suhe

  • 138.87M

    MRK Cap

  • 0.00%

    DIV tootlus

Adicet Bio, Inc. (ACET) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete Adicet Bio, Inc. (ACET) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 285.157 M, mis on 0.645 % gowth. Kogu perioodi keskmine brutokasum on 86.29 M, mis on 0.911 %. Keskmine brutokasumi suhtarv on 0.462 %. Ettevõtte eelmise aasta tulemuse puhaskasv on 1.128 %, mis on võrdne -1689.238 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes Adicet Bio, Inc. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus -0.373. Käibevara valdkonnas on ACET aruandlusvaluutas 162.272. Märkimisväärne osa neist varadest, täpsemalt 159.711, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust -0.380%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 0, kui neid on, aruandlusvaluutas. See näitab erinevust 0.000% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 17.703 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on -0.005%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 170.175 aruandlusvaluutas. Selle aspekti aastane muutus on -1.715%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 0, varude hind on 0 ja firmaväärtus 0, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 0.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008

balance-sheet.row.cash-and-short-term-investments

780.07159.7257.7277.5
94.6
62.4
108
53.3
67.7
37.4
43.6
35.4
26.4
29.6
31.2
58.3
47.1

balance-sheet.row.short-term-investments

0000
10.3
51.8
101
2
0.9
3.4
0.7
2.1
1.5
0.9
0.3
0.5
0.5

balance-sheet.row.net-receivables

1.2300.40.2
2.7
0.9
0
260.9
167.6
161.5
122.7
90.1
74.7
83.7
74.7
0
0

balance-sheet.row.inventory

6.3902.64.7
-3.1
0.7
0
136.4
98.1
95.6
100.7
83.8
84.7
77.4
74.9
54.4
71.1

balance-sheet.row.other-current-assets

3.942.60.40
0.4
0.2
1.5
0.9
19.2
15.8
9.3
9
6.2
7.8
14.8
58.9
75.6

balance-sheet.row.total-current-assets

791.62162.3261282.4
94.6
64.2
109.5
54.2
352.7
310.3
276.4
218.3
192
198.6
195.6
171.6
193.8

balance-sheet.row.property-plant-equipment-net

188.7644.24935
25.9
2.1
0.3
0
10
10.5
11.6
11.4
11.7
12.1
6.9
4.2
4.3

balance-sheet.row.goodwill

38.92019.519.5
20.1
0
0
237
67.9
67.9
66.5
33.5
33.5
33.6
1.7
1.9
2

balance-sheet.row.intangible-assets

0000
1.2
0
0
285.1
79.1
79
88
40.8
45.3
50.7
12.4
11.5
5.4

balance-sheet.row.goodwill-and-intangible-assets

38.92019.519.5
21.3
0
0
522.1
146.9
146.9
154.5
74.4
78.7
84.3
14.1
13.4
7.4

balance-sheet.row.long-term-investments

0000.1
4.5
10.6
0.1
-541.5
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

000-0.1
-4.5
0
0
19.5
18.1
10
11.6
8.1
4.7
0
0
0
0

balance-sheet.row.other-non-current-assets

3.850.81.22
12.1
4.7
0
-540.6
13.1
12.2
14
11.3
12.1
0
0
0
0

balance-sheet.row.total-non-current-assets

231.544569.756.5
59.2
17.4
0.4
1
188.1
179.5
191.6
105.1
107.3
96.4
21
17.6
11.7

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

1023.16207.3330.7338.9
153.8
81.6
109.9
55.2
540.8
489.8
468
323.4
299.3
295
216.6
189.3
205.5

balance-sheet.row.account-payables

12.562.64.43.3
1.6
1.1
3
1.5
46
55
48.7
39.2
42
44.6
40
25.1
43.5

balance-sheet.row.short-term-debt

12.343.22.51.6
1.2
0
0
14.5
0.2
10.2
8.3
11.7
6.7
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0.1
2.1
0
6.4
4
0.8
0
0
0
0

balance-sheet.row.long-term-debt-total

76.5217.718.519.4
20.4
114.1
3.1
339.2
118.6
100
97.2
20.4
39.1
6.2
33.6
20.7
19.9

Deferred Revenue Non Current

0000
224.7
10.9
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

51.0913.412.86.7
-2.8
2.8
2.7
-10.7
49.4
57.8
61
38.3
24.9
37.8
32.8
20.2
19.8

balance-sheet.row.total-non-current-liabilities

77.0417.818.619.5
246.2
127.1
0
408
134.1
107.6
108.8
33.8
52
6.2
33.6
20.7
19.9

balance-sheet.row.other-liabilities

0000
-216.2
0
0
-408
3.4
3
7.1
5.1
5.6
61.4
-16
-3.8
-3.1

balance-sheet.row.capital-lease-obligations

85.6417.72120.9
21.6
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

153.0337.138.435.8
44
142
5.7
5.5
236.3
235.6
234.4
128.8
131.3
150.8
92.2
63.9
81.8

balance-sheet.row.preferred-stock

000338.9
153.8
116
38.1
81.6
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

0.02000
0
0
0
0
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.3

balance-sheet.row.retained-earnings

-1302.45-380.8-238.1-168.3
-106.3
-69.6
-71.4
-33.8
194.8
167.2
140.8
118.6
102.3
90.7
87
85.5
81.8

balance-sheet.row.accumulated-other-comprehensive-income-loss

000-338.9
0
0
0
-5.1
-6.3
-7.1
5.4
2.9
1.3
7.7
1
7.5
13.1

balance-sheet.row.other-total-stockholders-equity

1637.35550.900
-153.9
-106.7
137.6
7
115.7
93.8
87.2
72.8
64.1
62.1
51.5
48.3
45.3

balance-sheet.row.total-stockholders-equity

334.92170.2-238.1-168.3
-106.3
-60.4
104.2
49.7
304.4
254.2
233.6
194.6
168
160.8
139.6
141.6
140.4

balance-sheet.row.total-liabilities-and-stockholders-equity

487.95207.3-199.8-132.5
153.8
81.6
109.9
55.2
540.8
489.8
468
323.4
299.3
295
216.6
189.3
205.5

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

334.92170.2-238.1-168.3
-106.3
-60.4
104.2
49.7
304.4
254.2
233.6
194.6
168
160.8
139.6
141.6
140.4

balance-sheet.row.total-liabilities-and-total-equity

487.95---
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

0000.1
10.3
62.4
101.1
2
0.9
3.4
0.7
2.1
1.5
0.9
0.3
0.5
0.5

balance-sheet.row.total-debt

88.8620.92120.9
21.6
114.1
3.1
353.7
118.8
110.2
105.5
32.1
45.8
55
33.6
20.7
19.9

balance-sheet.row.net-debt

-691.21-138.8-236.6-256.6
-62.7
103.5
-3.9
300.3
52
76.1
62.6
-1.2
20.9
26.3
2.7
-37
-26.6

Rahavoogude aruanne

Adicet Bio, Inc. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab -0.595 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 0.39, mis tähistab 0.000 erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli -4464000.000. See on -0.734 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 6.1, 0, 0, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte 0 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui -0.15, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008

cash-flows.row.net-income

-142.66-142.7-69.8-62
-36.7
-28.1
-9.3
34.8
33.5
29
22.3
22.3
17
9
6.6
8.6
13.5

cash-flows.row.depreciation-and-amortization

6.16.12.61.5
1.2
1.2
1.2
16.2
11.8
8.1
6.9
6.9
6.9
5.5
2.8
1.9
2.4

cash-flows.row.deferred-income-tax

9.71-34.101.2
3.2
0
0
0
1.9
3.1
2.6
2.6
1.8
-0.7
-0.8
0.2
-121.5

cash-flows.row.stock-based-compensation

20.2620.317.112.5
5.3
1.2
2.5
6.7
4.5
3.2
1.8
1.8
1.2
0.9
1
1.6
1.3

cash-flows.row.change-in-working-capital

0.250.32.7-6.1
-13.5
0.3
-8
68.4
27.5
29.4
10.1
2.9
-5.5
-3.8
-4.1
144.7
121.5

cash-flows.row.account-receivables

000.20
0
0
0
-6.1
-44.2
-19.4
-15
-15
5.7
1.9
-30.9
18.4
-7.3

cash-flows.row.inventory

0002
0
0
0
-2.5
-0.2
-7.8
1.6
1.6
-9.9
2.2
0.9
14.8
0

cash-flows.row.account-payables

-1.68-1.71.71.1
-0.8
0.5
-0.3
-8.9
8.1
5.2
-3.2
-3.2
-1
2.5
16.2
-17.3
0

cash-flows.row.other-working-capital

1.941.90.8-9.2
-12.7
-0.2
-7.8
86
63.8
51.4
26.6
19.5
-0.3
-10.4
9.7
-15.9
7.3

cash-flows.row.other-non-cash-items

12.6256.52.61.7
-1
-2.5
-4.5
-94.3
-70.9
-47.7
-18.3
-12.9
-8.1
3.2
-21
-134.4
-1.7

cash-flows.row.net-cash-provided-by-operating-activities

-93.72000
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-4.46-4.5-16.8-13
-1
-1.1
-0.9
-1.1
-0.6
-1.1
-1
-1
-1.1
-5.4
-4
-0.6
-1.2

cash-flows.row.acquisitions-net

0000
64.1
0.1
0
0
0
-86.1
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

0000
-5.7
-76.1
-15.2
-2
0
-2.7
-0.1
-2.7
-1.2
-0.5
0
-10.2
0

cash-flows.row.sales-maturities-of-investments

00010.3
57.8
29.1
7.5
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

0000
0
0
-7.5
-6.7
-8.3
4.1
-1.7
2.7
0.5
-63.3
-2.1
6.7
2.6

cash-flows.row.net-cash-used-for-investing-activites

-4.46-4.5-16.8-2.8
115.2
-47.9
-16.1
-9.9
-9
-85.9
-2.8
-1.1
-1.8
-69.2
-6.1
-4.1
1.4

cash-flows.row.debt-repayment

0000
0
0
0
-122.7
-14.3
-40.7
-23.7
-23.7
-9.2
0
0
0
0

cash-flows.row.common-stock-issued

0.390.443.4238.1
0.1
76.9
0
25
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

-0.15-0.1-3.20
0
0
0
-55.7
-66.8
-34
-42.9
-33.2
-24.9
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
-7.1
-7
-6.8
-6
-6
-5.3
-5.2
-5.1
-4.9
0

cash-flows.row.other-financing-activites

0.08-0.1-1.94.6
0.2
76.9
11
171.3
79.9
152.1
58.3
48.6
24.1
55.2
2.6
0.7
-6

cash-flows.row.net-cash-used-provided-by-financing-activities

0.240.241.5242.7
0.3
76.9
11
10.9
-8.2
70.5
-14.3
-14.3
-15.3
50
-2.4
-4.3
-6

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
-4.1
0.7
0.4
0.4
-1.7
3
-2.9
-2.9
3.4

cash-flows.row.net-change-in-cash

-97.94-97.9-20188.8
74
1.1
-23.2
32.8
-8.9
9.7
8.4
8.4
-3.8
-2.2
-26.9
11.2
14.2

cash-flows.row.cash-at-end-of-period

780.07159.7257.7277.7
88.9
14.9
13.8
55.7
66.8
34
42.9
33.2
24.9
28.7
30.9
57.8
46.5

cash-flows.row.cash-at-beginning-of-period

878.01257.7277.788.9
14.9
13.8
36.9
22.9
75.7
24.4
34.5
24.9
28.7
30.9
57.8
46.5
32.3

cash-flows.row.operating-cash-flow

-93.72-93.7-44.8-51.1
-41.6
-27.9
-18.2
31.8
8.3
25.1
25.5
23.7
13.3
14
-15.5
22.5
15.4

cash-flows.row.capital-expenditure

-4.46-4.5-16.8-13
-1
-1.1
-0.9
-1.1
-0.6
-1.1
-1
-1
-1.1
-5.4
-4
-0.6
-1.2

cash-flows.row.free-cash-flow

-98.18-98.2-61.5-64.1
-42.5
-29
-19.1
30.7
7.7
23.9
24.5
22.7
12.2
8.6
-19.5
22
14.2

Kasumiaruande rida

Adicet Bio, Inc. tulud muutusid võrreldes eelmise perioodiga -1.000%. ACET brutokasum on teatatud -6.1. Ettevõtte tegevuskulud on 126.48, mille muutus võrreldes eelmise aastaga on 29.666%. Kulud amortisatsioonikulud on 6.1, mis on 1.146% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 126.48, mis näitab 29.666% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab -0.827% kasvu võrreldes eelmise aastaga. Tegevustulu on -132.58, mis näitab 0.827% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on 1.128%. Eelmise aasta puhaskasum oli -142.66.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008

income-statement-row.row.total-revenue

00259.7
17.9
1
8.2
558.5
547
510.2
499.7
499.7
444.4
412.4
346.6
322.6
359.6

income-statement-row.row.cost-of-revenue

8.146.150
0
0.1
0.1
0
411.5
395.5
401.4
401.4
362.4
346.6
292.5
267
292.3

income-statement-row.row.gross-profit

-8.14-6.1209.7
17.9
0.9
8.1
558.5
135.4
114.7
98.3
98.3
82
65.8
54.2
55.6
67.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

106.04---
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

26.53---
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

-1.69---
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-0.5719.5-0.9-0.6
-1
2.3
4.5
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.operating-expenses

130.89126.597.571.2
57.1
32.4
23.1
18.9
0
70.4
63.9
63.9
56.7
49.3
44.7
43.7
45.9

income-statement-row.row.cost-and-expenses

132.58132.697.571.2
57.1
32.4
23.1
18.9
0
465.9
465.3
465.3
419
395.9
337.2
310.8
338.2

income-statement-row.row.interest-income

9.98103.80.1
0.8
0.9
0.5
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

0.0200.10.2
0.1
0
0
7
4
2.1
2.1
2.1
2.6
1.6
0.2
0.1
0.1

income-statement-row.row.selling-and-marketing-expenses

-1.69---
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-15.21-10.12.8-0.7
-0.3
3.3
4.5
-14.9
-2.5
0.4
0.1
0.1
-0.6
0.4
0.8
0.8
0.8

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-0.5719.5-0.9-0.6
-1
2.3
4.5
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.total-operating-expenses

-15.21-10.12.8-0.7
-0.3
3.3
4.5
-14.9
-2.5
0.4
0.1
0.1
-0.6
0.4
0.8
0.8
0.8

income-statement-row.row.interest-expense

0.0200.10.2
0.1
0
0
7
4
2.1
2.1
2.1
2.6
1.6
0.2
0.1
0.1

income-statement-row.row.depreciation-and-amortization

7.36.12.8-0.5
-0.2
4.5
1.2
0
11.8
8.1
6.9
6.9
6.9
5.5
2.8
1.9
2.4

income-statement-row.row.ebitda-caps

-120.41---
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-152.04-132.6-72.6-61.4
-39.2
-31.4
-15
-18.9
0
44.3
34.4
34.4
25.4
16.6
9.4
11.9
21.4

income-statement-row.row.income-before-tax

-142.66-142.7-69.8-62.1
-39.5
-28.1
-9.9
-33.8
0
44.7
34.5
34.5
24.7
17
10.2
12.7
22.2

income-statement-row.row.income-tax-expense

-1.510-2.8-0.1
-2.8
0
-0.6
19.1
20.4
15.7
12.2
12.2
7.8
8
3.6
4.1
8.7

income-statement-row.row.net-income

-141.4-142.7-67-62
-36.7
-28.1
-9.3
-33.8
0
29
22.3
22.3
17
9
6.6
8.6
13.5
Sarnased aktsiad
Sind võib huvitada ka:
SRNE
Sorrento Therapeutics, Inc..
0.016 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
9.01 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.0212 USD
NASDAQ
GUBRA.CO
Gubra A/S.
309 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.4 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

Korduma kippuv küsimus

Mis on Adicet Bio, Inc. (ACET) koguvara?

Adicet Bio, Inc. (ACET) koguvara on 207295000.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on N/A.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.000.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on -2.281.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on 0.000.

Mis on ettevõtte kogutulu?

Kogutulu on 0.000.

Mis on Adicet Bio, Inc. (ACET) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on -142658000.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 20924000.000.

Mis on tegevuskulude arv?

Tegevuskulud on 126478000.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 159711000.000.